Forward Looking Statements

Included in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements will prove to have been correct. The Company’s actual results could differ materially from those anticipated in the forward-looking statements as a result of certain factors including sales levels, distributions, and competition trends and other market factors.

Legal Disclosure

OTC Signal is an independent electronic publication providing both information and factual analysis on selected companies. Companies featured by OTC Signal pay consideration to OTC Signal for the electronic dissemination of company information. All statements and expressions are the opinion of OTC Signal and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. OTC Signal is not a registered investment advisor or a broker dealer. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk including the potential los of all capital invested. The information that OTC Signal relies on is generally provided by the featured companies and may also include information from outside sources and interviews conducted by OTC Signal. While OTC Signal believes all sources of the information to be reliable, OTC Signal makes no representation or warranty as to the accuracy of the information provided. Readers should not rely solely on the information contained in this publication, but should use the information contained in this publication as a starting point for doing additional independent research on the featured companies in order to allow the reader to form their own opinion regarding investing in featured companies. Factual statements in this publication are made as of the date stated and are subject to change without notice. The publisher is not responsible for any claims made by the company. The receipt of this publication shall not create, under any circumstance, any implication that there has been no change in the affairs of the company profiled since the date of review.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements invoke risk and uncertainties and the company’s actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company’s products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

This publication is an advertisement on behalf of the of the Company and may not be construed as investment advice. This advertisement does not provide an analysis of the Company’s financial position and is not a solicitation to purchase or sell securities of the Company. Readers should consult with their own independent financial analyst. The Publisher, its affiliates, officers, directors, subsidiaries and agents (collectively the “Publisher”) of this advertisement has been compensated by the Company. Compensation included in preparing this advertisement is not an endorsement of the Company by the Publisher. Each reader should independently investigate and fully understand all risks before investing. OTC Signal has been paid the following compensation for the dissemination of the Newsletter. Such compensation received by OTC Signal for its services should be viewed by readers as a potential conflict of interest.

Readers Caution

This publication is an advertisement on behalf of the Companies whose article and/or information appear herein and may not be construed as investment advice. All articles, notices, and other information contained herein concerning a Company(s) is a paid advertisement by such Company, which has retained the Publisher to produce this advertisement. No analysis has been made by the Publisher. The information contained herein is based upon sources which we consider reliable but is not guaranteed by OTC Signal or its officers, directors, employees, or any affiliated parties. The advertisements are not a solicitation to purchase or hold, or dispose of stock securities of an advertising company. Readers should consult with their own independent tax, business and financial advisors with respect to any investment opportunity, including and contemplated investment in the advertised Company(s). Such compensation received by OTC Signal for its services should be viewed by readers as a potential conflict of interest. All information concerning a Company advertising herein and contained in this publication should be verified independently with such company and an independent securities analyst. The Publisher, its affiliates, officers, directors, subsidiaries, and agents, (collectively, the “Publisher”) of this newsletter have been compensated by the Companies advertising herein, which compensation may include shares of stock of any Company advertising herein which is held by the Publisher. Copyright 2009 OTC Signal. All rights reserved. This publication or part hereof may not be duplicated or reprinted without permission of the Publisher. Facsimile including photocopy(s) is strictly forbidden, except for facsimile correspondence between OTC Signal and the 102 countries it distributes to. If this publication contravenes any securities laws and/or regulations, the securities regulations of the country will prevail. In which case that this issue does not offend such regulation this issue must be discarded.

Compensation Disclosure:  Aquentium has agreed to pay OTC Signal $12,000 for 12 months of advertising.